Even before Scott Gottlieb took the top job at the Food and Drug Administration, there were signs his tenure would be different.

For one, he had ties to the pharmaceutical industry — he served on company boards, he worked in venture capital firms that invested in health care companies, and he was a resident fellow at the American Enterprise Institute, a conservative think tank that supports deregulation.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • What disappointed me most about Gottlieb was his failure to end the FDA ban on genetically modified salmon. After a twenty seven year investigation, FDA finally agreed in Nov 2015 that it was safe to eat and safe for the environment, but immediately after finding it safe, FDA issued a ban on raising it and selling it in the United States until FDA could issue a rule about how it should be labeled at point of sale. Then FDA also said that it had no authority to issue such a labeling rule, but continued the ban. Finally, after Congress passed a law that required all GMO foods to be labeled in accordance to a rule from USDA, that USDA rule was issued late last year, but FDA still won’t lift its ban for the tenuous reason that the labeling rule wouldn’t count because it didn’t come from FDA. This makes catch-22 look like child’s play.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy